| 货号 | 13346-1mg |
| 描述 | Rapamycin is an immunosuppressant that is used primarily to prevent the rejection of organ and bone marrow transplant. It was first described as a potent inhibitor of IL-2 activation of lymphocytes (IC50 = 5 pM).1 It is now known that rapamycin specifically interacts with the cytosolic FK-binding protein 12 (FKBP12) to form a complex which inhibits the mammalian target of rapamycin (mTOR) pathway by directly binding to mTOR Complex 1 (mTORC1). Rapamycin and other inhibitors of mTORC1 signaling show potential in treating cancer, adipogenesis, diabetes, tuberous sclerosis, and cardiovascular disease.2,3,4 |
| 别名 | Sirolimus; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Kay, J.E.,Kromwel, L.,Doe, S.E.A., et al. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 72(4), 544-549 (1991). 2.Akcakanat, A.,Zhang, L.,Tsavachidis, S., et al. The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Molecular Cancer 8(75), (2009). 3.Zhang, H.H.,Huang, J.,Düvel, K., et al. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One 4(7), (2009). 4.Balgi, A.D.,Fonseca, B.D.,Donohue, E., et al. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 4(9), 1-15 (2009). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 914.2 |
| 分子式 | C51H79NO13 |
| CAS号 | 53123-88-9 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |